Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-10-15

Clinical Trial Update: Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease [Phase 4]

View source ↗

Summary

Phase 4 trial results posted for rasagiline as an add-on therapy to dopamine agonists in Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rasagiline (Azilect) (rasagiline)

Snippet

Sponsor: Teva Neuroscience, Inc. | Conditions: Parkinson's Disease | Phase 4 | Status: COMPLETED | Results posted: 2014-10-15